1. Encouraging development of vaccines for opioid, cocaine, methamphetamine, or alcohol use disorder (a) Breakthrough therapies Section 506(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356(a) ) is amended by adding at the end the following: (4) Vaccines for opioid, cocaine, methamphetamine, or alcohol use disorder (A) In general If a request is submitted under paragraph (1) for a vaccine to prevent, treat, or mitigate an opioid use disorder (including such a disorder related to fentanyl), a cocaine use disorder, a methamphetamine use disorder, or an alcohol use disorder, such vaccine is deemed to be a breakthrough therapy. (B) Sunset Subparagraph (A) shall cease to be effective on the date that is 10 years after the date of enactment of this paragraph. . (b) Fast track products Section 506(b) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356(b) ) is amended by adding at the end the following: (4) Vaccines for opioid, cocaine, methamphetamine, or alcohol use disorder (A) In general If a request is submitted under paragraph (1) for a vaccine to prevent, treat, or mitigate an opioid use disorder (including such a disorder related to fentanyl), a cocaine use disorder, a methamphetamine use disorder, or an alcohol use disorder, such vaccine is deemed to be a fast track product. (B) Sunset Subparagraph (A) shall cease to be effective on the date that is 10 years after the date of enactment of this paragraph. . (c) Priority review (1) In general The Secretary of Health and Human Services shall give priority review to any application for a vaccine to prevent, treat, or mitigate an opioid use disorder (including such a disorder related to fentanyl), a cocaine use disorder, a methamphetamine use disorder, or an alcohol use disorder that is submitted under— (A) section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 )